Does Infliximab Influence Surgical Morbidity of Ileal Pouch-Anal Anastomosis in Patients with Ulcerative Colitis?

• DOI: 10.1007/s10350-007-9008-3
• Publication Date: 2007-08-17T07:58:04Z
• Authors: Stefanie J. Schlu...; Andrew Ippoliti; Marla Dubinsky; Eric A. Vasiliauskas; Konstantinos A. P...; Ling Mei; Stephan R. Targan; Phillip R. Fleshner
• Keywords: Refractory (planetary science); Colorectal Surgery; Pouch; Proctocolectomy

Since infliximab has been approved for treatment of patients with refractory ulcerative colitis, surgeons will be increasingly faced operating on who have failed therapy this potent immunosuppressant. This study was designed to compare short-term complications in colitis were treated and without before colectomy.The charts undergoing ileal pouch-anal anastomosis or subtotal colectomy during the five-year period ending October 2005 reviewed. Postoperative medical surgical assessed.Seventeen had 134 never infliximab. Ileal performed 112 (74 percent) 39 (36 percent). There no deaths. observed 43 (28 percent), significant difference between infliximab-treated (37 infliximab-untreated (27 Of 61 (40 preoperative cyclosporine A, 5 also The A-treated patient group an 80 percent complication rate, significantly higher than 29 rate noted A only-treated (P = 0.04).Although alone does not increase incidence postoperative complications, using both inflixiamb is associated high morbidity.